NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ZJYL
Jin Medical International Ltd.
There isn't enough reported data to score ZJYL yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ZJYL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Weak |
ZJYL's profitability is currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue and cash flow.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ZJYL in the historical PE scenario, which offers more potential upside but is not a forecast.
ZJYL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $2.19 | -43% |
| Fair | 18x | $3.67 | -5.1% |
| Current | 21x | $3.87 | — |
| Expensive | 161x | $32.23 | +733% |
Historical ranges are pointers, not guarantees.
ZJYL's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ZJYL Forward outlook
There aren't enough analyst estimates for ZJYL to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ZJYL Earnings Per Share
ZJYL and NVO do not have enough comparable growth data to identify a winner.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ZJYL in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ZJYL on profitability, with a higher operating margin.
ZJYL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $8.9M | -9.7% |
| Q3 2025 | $10.8M | -17% |
| Q1 2025 | $9.9M | -6.4% |
| Q3 2024 | $12.9M | +35% |
| Q1 2024 | $10.6M | +3% |
| Q3 2023 | $9.6M | -1.6% |
| Q1 2023 | $10.3M | +8.3% |
| Q3 2022 | $9.7M | -14% |
ZJYL's revenue is growing: $9M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7.2% | -19 points |
| Q3 2025 | 9.8% | -1.6 points |
| Q1 2025 | -4.6% | -22 points |
| Q3 2024 | 19% | +7.1 points |
| Q1 2024 | 12% | +0.9 points |
| Q3 2023 | 11% | +4.5 points |
| Q1 2023 | 17% | -2.3 points |
| Q3 2022 | 11% | -1.6 points |
ZJYL's operating margin was −7.2% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ZJYL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.7M | -633% |
| Q3 2025 | -$4.2M | -$2.9M |
| Q1 2025 | $510.9K | +$544.6K |
| Q3 2024 | -$1.3M | -607% |
| Q1 2024 | -$33.7K | -101% |
| Q3 2023 | $260K | -84% |
| Q1 2023 | $2.7M | +$2.8M |
| Q3 2022 | $1.6M | -19% |
ZJYL's free cash flow was −$8M over the past year, against $5M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ZJYL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ZJYL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2 shares |
| 1 year | +0.1% | +7.3K shares |
| 3 years | -61% | -12.2M shares |
ZJYL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2022 | — |
| Q1 2022 | — |
| Q3 2021 | — |
| Q1 2021 | — |
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ZJYL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 13.4x | High |
| Q1 2025 | 2.1x | Moderate |
| Q3 2024 | 0.8x | Very low |
| Q1 2024 | 0.3x | Very low |
ZJYL's net debt is about 13 years of its operating earnings (EBITDA).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ZJYL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 61.8 | Neutral |
ZJYL's weekly RSI is 66 (neutral) and its Stochastic is 62 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ZJYL on valuation relative to its sector.
ZJYL PE vs Healthcare Sector
| Metric | ZJYL | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 55 | 39 | 16 pts above |
ZJYL is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
ZJYL has stronger trend alignment. NVO is above 1 of 5 weekly averages versus ZJYL above 3 of 4.
ZJYL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.45 | 58% above |
| 20 week MA | $2.32 | 67% above |
| 50 week MA | $2.64 | 47% above |
| 100 week MA | $8.05 | 52% below |
ZJYL has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 52% below its 100-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
ZJYL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $7.45 | $248.1 | +3230% |
| 2024 | $248.1 | $21.0 | -92% |
| 2025 | $21.0 | $4.46 | -79% |
| 2026 YTD | $4.46 | $3.87 | -13% |
ZJYL has the edge over NVO on returns for 2026, with the stronger performance.